Leadership
LEADERSHIP
We're Driving Innovations with A World-Class Team
Meet the team
Our Management
A World Class Leadership Team Driving Innovation

Krishnan (Nandu) Nandabalan, Ph.D.
President and CEO

Krishnan (Nandu) Nandabalan, Ph.D.
President and CEO
He served as VP of Corporate Development at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and its widespread cceptance. Before this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and was a Post-Doctoral Fellow at Yale University, Connecticut.

Aman Kant
Chief Business Officer

Aman Kant
Chief Business Officer
Prior to joining InveniAI, Mr. Kant played a significant role in the parent Company, BioXcel LLC, where he led the assessment and negotiation of numerous collaborations that expanded and strengthened the value proposition of big data analytics and AI tools across the pharmaceutical R&D value chain. Mr. Kant has forged strong relationships with key opinion leaders and industry executives with a focus on bringing people together to ultimately impact human health and wellness. Mr. Kant holds a B.Tech in Biotechnology.

Madan Anant, Ph.D.
Chief Scientific Officer

Madan Anant, Ph.D.
Chief Scientific Officer

Sameer Sharma, Ph.D.
Vice President & Head, Translational Drug Discovery

Sameer Sharma, Ph.D.
Vice President & Head, Translational Drug Discovery
As the previous lead researcher for translational and nonclinical research at BioXcel Therapeutics, he was instrumental in the discovery of BXCL501 (IGALMI™), a sublingual film designed to support a cooperative approach to agitation intervention, which was successfully launched in 2022. He has also identified various novel disease-drug combinations in CNS, hematology, and other disease areas using artificial Intelligence tools and big data analytics that were validated using cell line, animal, and early clinical proof of concept (POC) studies.
In addition, Dr. Sharma has extensive experience in conducting multi-year research focused on autoimmune, respiratory, and metabolic diseases. As a translational expert, he has provided high-level strategic insights and recommendations to the biopharma industry for developing novel drugs and prioritizing target-indication programs across multiple therapeutic areas.
As a Program Leader at Daiichi Sankyo and Ranbaxy Research Laboratories, he led and delivered various projects and collaborations and provided scientific insights for multi-disciplinary drug discovery teams. Dr. Sharma has a stellar record of accomplishment in the scientific community with in-depth knowledge of newer technologies and advances in pharmacology, a strong patent portfolio and numerous publications in peer-reviewed scientific journals. He has received several awards in the past for outstanding achievements in the field.
He has a bachelor's degree in pharmacy and holds a master's and Ph.D. degreenin pharmacology from Panjab University, Chandigarh, India.

Govindan Vijayadamodar, Ph.D., MBA
Vice President, AI & Analytics

Govindan Vijayadamodar, Ph.D., MBA
Vice President, AI & Analytics

Sanatan Upmanyu
Head of Data Sciences and Switzerland Site Head

Sanatan Upmanyu
Head of Data Sciences and Switzerland Site Head
Sanatan has contributed to numerous scientific projects, patents, and publications, showcasing his deep domain knowledge. His leadership in exploratory data analysis and experimental design has provided actionable insights into market trends and disease mechanisms, enabling the development of impactful strategies and solutions.
As Head of Data Sciences, Sanatan leads the design, development, and delivery of the AlphaMeld® and ChatAlphaMeld platforms, which integrate artificial intelligence and data science to transform drug discovery and development. Based in Basel, Switzerland, he also oversees the growth and operations of the company’s European business.
Sanatan holds a B.Tech in Biotechnology and brings a strategic perspective that bridges science, technology, and business innovation.

Anita Ganjoo, Ph.D.
Vice President, External Communications

Anita Ganjoo, Ph.D.
Vice President, External Communications
She has primarily worked for start-ups that have grown through to IPO. She previously worked for BioXcel LLC, where she headed their corporate communications, and prior to this, she worked in scientific communications at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and personalized medicine.
She completed two Post-Doctoral Fellowships at Lund University, Sweden, and at The University of Reading, UK, where she also received her Ph.D. in Biotechnology. She is the author of numerous publications and a book chapter on the applications of aqueous two-phase systems in protein purification.
Meet the team
A World Class Leadership Team Driving Innovation

Krishnan (Nandu) Nandabalan, Ph.D.
President and CEO

Krishnan (Nandu) Nandabalan, Ph.D.
President and CEO
He served as VP of Corporate Development at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and its widespread acceptance. Before this, he was the Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and has been published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and was a Post-Doctoral Fellow at Yale University, Connecticut.

Amit Agrawal, Ph.D.
Chief Scientific Officer for the Diagnostics Platform, Danaher Corporation

Amit Agrawal, Ph.D.
Chief Scientific Officer for the Diagnostics Platform, Danaher Corporation

Demetrios Kydonieus
President, R-Pharm

Demetrios Kydonieus
President, R-Pharm

Jonathan Zalevsky Ph.D.
Chief Research & Development Officer, Nektar Therapeutics

Jonathan Zalevsky Ph.D.
Chief Research & Development Officer, Nektar Therapeutics

Ramesh Cidambi
Entrepreneur and Business Executive

Ramesh Cidambi
Entrepreneur and Business Executive